Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

A precision medicine initiative for Alzheimer's disease: the road ahead to biomarker-guided integrative disease modeling

Hampel, H., O'Bryant, S. E., Durrleman, S., Younesi, E., Rojkova, K., Escott-Price, Valentina, Corvol, J-C., Broich, K., Dubois, B. and Lista, S. 2017. A precision medicine initiative for Alzheimer's disease: the road ahead to biomarker-guided integrative disease modeling. Climacteric 20 (2) , pp. 107-118. 10.1080/13697137.2017.1287866

[img]
Preview
PDF - Accepted Post-Print Version
Download (334kB) | Preview

Abstract

After intense scientific exploration and more than a decade of failed trials, Alzheimer’s disease (AD) remains a fatal global epidemic. A traditional research and drug development paradigm continues to target heterogeneous late-stage clinically phenotyped patients with single 'magic bullet' drugs. Here, we propose that it is time for a paradigm shift towards the implementation of precision medicine (PM) for enhanced risk screening, detection, treatment, and prevention of AD. The overarching structure of how PM for AD can be achieved will be provided through the convergence of breakthrough technological advances, including big data science, systems biology, genomic sequencing, blood-based biomarkers, integrated disease modeling and P4 medicine. It is hypothesized that deconstructing AD into multiple genetic and biological subsets existing within this heterogeneous target population will provide an effective PM strategy for treating individual patients with the specific agent(s) that are likely to work best based on the specific individual biological make-up. The Alzheimer’s Precision Medicine Initiative (APMI) is an international collaboration of leading interdisciplinary clinicians and scientists devoted towards the implementation of PM in Neurology, Psychiatry and Neuroscience. It is hypothesized that successful realization of PM in AD and other neurodegenerative diseases will result in breakthrough therapies, such as in oncology, with optimized safety profiles, better responder rates and treatment responses, particularly through biomarker-guided early preclinical disease-stage clinical trials.

Item Type: Article
Date Type: Published Online
Status: Published
Schools: Medicine
MRC Centre for Neuropsychiatric Genetics and Genomics (CNGG)
Subjects: R Medicine > R Medicine (General)
Uncontrolled Keywords: Alzheimer’s disease, precision medicine, precision medicine initiative, Alzheimer precision medicine initiative, systems biology, systems medicine, biomarkers, integrative disease modeling
Publisher: Taylor & Francis
ISSN: 1369-7137
Date of First Compliant Deposit: 30 March 2017
Date of Acceptance: 8 December 2016
Last Modified: 15 Feb 2018 03:30
URI: http://orca-mwe.cf.ac.uk/id/eprint/99497

Citation Data

Cited 38 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item

Downloads

Downloads per month over past year

View more statistics